The Pharma Data

NOVEMBER 9, 2020

Food and Drug Administration (FDA) has granted Fast Track Designation for NVX-CoV2373, the Company’s COVID-19 vaccine candidate. NVX-CoV2373 contains purified protein antigen and cannot replicate, nor can it cause COVID-19. GAITHERSBURG, Md., 09, 2020 (GLOBE NEWSWIRE) — Novavax, Inc. and Australia. About Fast Track Designation.

Vaccination 52

Vaccination Vaccine Clinical Trials Clinical Trials 52

The Pharma Data

DECEMBER 16, 2020

Food and Drug Administration, European Medicines Agency and/or Medicines and Healthcare products Regulatory Authority in the United Kingdom. NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Additional terms of the agreement were not disclosed. and Australia.

Protein 52

Protein Vaccination Vaccine Immune Response 52

The Pharma Data

JULY 27, 2021

Acquisition Complements Amgen’s Antibody Research Capabilities Across Therapeutic Areas Acquisition Includes a Portfolio of Early-Stage Oncology Assets, Including a Phase 1 Bispecific Antibody for Patients With Advanced Prostate Cancer. billion in cash. Reese, M.D., executive vice president of Research and Development at Amgen.

Production 52

Production Antibody Sales Manufacturing 52

The Pharma Data

NOVEMBER 30, 2020

Preliminary blinded data on NVX-CoV2373 in older adults needed to proceed to Phase 3 has previously been positively reviewed by the Food and Drug Administration (FDA). NVX-CoV2373 contains purified protein antigen and can neither replicate, nor can it cause COVID-19. Additional clinical data from the Phase 2 trial conducted in the U.S.

Clinical Development 52

Clinical Development Vaccination Vaccine Development 52

XTalks

AUGUST 17, 2020

Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Monoclonal antibodies : these are antibodies that are designed to bind to specific targets on cells. chimeric receptor antigen [CAR] T cell) immune modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

The Pharma Data

JANUARY 10, 2021

CERC-002 is a human anti-LIGHT monoclonal antibody. INZ-701 is a soluble, recombinant protein containing the extracellular domain of native human ENPP1 fused to the Fc domain of the immunoglobulin IgG1. The drug is an RNA interference (RNAi) therapeutic. Cerecor announced results from its exploratory Phase II U.S.-based

Gene Therapy 52

Gene Therapy Trials Gene Clinical Trials 52

pharmaphorum

NOVEMBER 2, 2021

Dr Laura Moriarty, senior marketing manager at Bio-Rad, looks at the impressive immuno-therapeutic potential of bispecific antibodies (bsAbs). Though their bispecific nature complicates large-scale production and purification workflows, with challenges such as antibody chain mispairing, bsAbs have come a long way since first developed.

Antibody 52

Antibody Immune Response Production Engineer 52